Summary

• Page properties (1 modified, 0 added, 0 removed)

Details

Page properties

Content

...	...	@@ -4,14 +4,16 @@
4	4
5	5	= Summary =
6	6
7		-The Company has a portfolio of over 150 products across 15 therapeutic areas with annual sales of over Rs. 2,000 crores.
	7	+* The Company has a portfolio of over 150 products across 15 therapeutic areas with annual sales of over Rs. 2,000 crores.
	8	+* Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others
8	8
9		-Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others
10	10
	11	+[[image:PFIZER0.jpg||height="334" width="594"]]
11	11
	13	+
12	12	= Company Overview =
13	13
14		-Pfizer Limited was listed on the Indian stock exchange in 1966. Today, the company has over one lac shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas. {{footnote}}https://www.pfizerindia.com/eNewsWebsite/about.aspx{{/footnote}}
	16	+Pfizer Limited (NSE: PFIZER) was listed on the Indian stock exchange in 1966. Today, the company has over one lac shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas. {{footnote}}https://www.pfizerindia.com/eNewsWebsite/about.aspx{{/footnote}}
15	15
16	16
17	17	Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.
...	...	@@ -19,12 +19,15 @@
19	19	The Company employs 2,631 colleagues, and is committed to providing therapies to prevent and treat some of the most critical diseases that impact public health in India today.
20	20
21	21
	24	+[[image:PFIZER2.png]]
	25	+
	26	+
22	22	= Industry Overview =
23	23
24	24
25	25	According to the Indian Economic Survey 2021, the domestic pharmaceutical market is expected to grow three times in the next decade to US$ 42 billion in 2021 and US$ 65 billion by 2024 and may reach ~~US$ 120-130 billion by 2030. {{footnote}}https://www.pfizerindia.com/eNewsWebsite/investor/pdf/Pfizer_Limited_Annual_Report_2020-21.pdf{{/footnote}}
26	26
27		-The Union Budget 2021 puts a spotlight on health and well-being. Doubling up healthcare spending and allocating a sizable outlay for developing capacities of primary, secondary and tertiary healthcare systems and promoting new and existing institutions to concentrate on emerging diseases over the next 6 years, is a welcome move. The focus is now on overall well-being of the people including preventive and curative health with a larger emphasis on immunization. Allocating ` 35,000 crore for COVID-19 vaccine and the assurance that any additional spending required would be provided for vaccination, is a welcome step. However, much needs to be done to improve national healthcare spending as a percentage of GDP.
	32	+The Union Budget 2021 puts a spotlight on health and well-being. Doubling up healthcare spending and allocating a sizable outlay for developing capacities of primary, secondary and tertiary healthcare systems and promoting new and existing institutions to concentrate on emerging diseases over the next 6 years, is a welcome move. The focus is now on overall well-being of the people including preventive and curative health with a larger emphasis on immunization. Allocating Rs 35,000 crore for COVID-19 vaccine and the assurance that any additional spending required would be provided for vaccination, is a welcome step. However, much needs to be done to improve national healthcare spending as a percentage of GDP.
28	28
29	29
30	30	== Indian Pharmaceutical Industry ==
...	...	@@ -32,7 +32,7 @@
32	32
33	33	=== Market Overview ===
34	34
35		-The Indian pharma market (IPM) grew at 4.3% over the April 2020 - March 2021 period, with a turnover of `1,56,797 Crore. The growth was primarily driven by price, which contributed 4.3% to the total, followed by new products at 3.6% and volume at -3.6%. Multinational companies hold about 20% share in the market and have grown at 2.6%.
	40	+The Indian pharma market (IPM) grew at 4.3% over the April 2020 - March 2021 period, with a turnover of  Rs 1,56,797 Crore. The growth was primarily driven by price, which contributed 4.3% to the total, followed by new products at 3.6% and volume at -3.6%. Multinational companies hold about 20% share in the market and have grown at 2.6%.
36	36
37	37
38	38	=== Therapeutic Growth ===
...	...	@@ -47,6 +47,9 @@
47	47	The impact was higher as the lockdown period overlapped with monsoon season which typically are growth drivers for acute therapeutic areas. With limited face-to-face detailing, new launches were either delayed or saw lower uptake but are now picking up. Vitamins has shown strong recovery driven by consumer awareness and their role in immunity building for COVID-19. The respiratory therapeutic area has shown lower growth levels. A research indicates lockdown linked drop in asthma attacks mainly due to lower levels of air pollution, fewer cold and flu infections. Limited access to healthcare professionals in Tier 1 Cities due to stricter lockdown, reverse migration, lower inter-district travel for medicine purchase and increased focus on rural markets are potential drivers for rural growth. Going forward, health systems needs to be mindful of increasing co-morbidities/ new diagnosis in COVID-19 recovered patients.
48	48
49	49
	55	+[[image:PFIZER4.png]]
	56	+
	57	+
50	50	= Business Overview =
51	51
52	52	The company collectively addresses 15 therapy areas with a portfolio of over 150 products that include therapeutics and vaccines.
...	...	@@ -123,6 +123,9 @@
123	123	Pfizer’s original breakthrough innovative and patented drug Zavicefta 2gm/0.5gm (ceftazidime-avibactam) has recorded an exponential growth driven by increased uptake across more number of hospitals. This novel drug is indicated for the management of hospital-acquired pneumonia including ventilator-associated pneumonia (HAP/VAP), complicated intra-abdominal infection (cIAI) and complicated urinary infection (cUTI) in adults. The emergence and spread of carbapenemase-producing pathogens are a concern and has highlighted the urgent need for new antimicrobial agents.
124	124
125	125
	134	+[[image:PFIZER3.jpg]]
	135	+
	136	+
126	126	= Financial Highlights =
127	127
128	128	**financial results for the quarter and year ended March 31, 2021.**